Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use
Open Access
- 2 June 2015
- journal article
- review article
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 4 (2) , 145-157
Abstract
Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies—informing on its efficacy, use, and adverse features—and there are also over 7.5 million patient-years of experience to date. We explore the data on this nucleotide reverse transcriptase inhibitor in HIV presented since 2008—focusing on efficacy, side effects, and utility.Keywords
This publication has 88 references indexed in Scilit:
- SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral RegimenClinical Infectious Diseases, 2013
- Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agentsAIDS, 2012
- Renal tubular dysfunction during long‐term adefovir or tenofovir therapy in chronic hepatitis BAlimentary Pharmacology & Therapeutics, 2012
- Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trialThe Lancet Infectious Diseases, 2011
- Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final ResultsThe Journal of Infectious Diseases, 2011
- Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202The Journal of Infectious Diseases, 2011
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with MenNew England Journal of Medicine, 2010
- Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) StudyThe Journal of Infectious Diseases, 2010
- Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 TherapyNew England Journal of Medicine, 2009
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004